cancer diagnostics

Analysts at Bank of America turned incrementally bullish on EXACT Sciences Corporation (NASDAQ: EXAS) after the company reported a clean beat and raise quarter. The firm's Anne Edelstein maintains a Buy rating on Exact Sciences' stock with a price target boosted from $56 to $58. Exact Sciences'...

EXACT Sciences Corporation (NASDAQ: EXAS) plummeted over 7 percent Monday on a Citron Research report predicting a 40-percent short-term value concession and long-term drop to a near-zero single digit. Citron's most important report in YEARS. $EXAS to trade short term $20. Long term much lower...